Olema Pharmaceuticals Inc (OLMA)
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker OLMA. The company focuses on discovering, developing, and commercializing therapies for women’s cancers. Its lead candidate, palazestrant, is an estrogen receptor antagonist and selective estrogen receptor degrader being studied in Phase 3 trials for recurrent, locally advanced, or metastatic ER-positive, HER2-negative breast cancer. Olema is also evaluating palazestrant in combination regimens, including use with CDK4/6 inhibitors, alpelisib, a mTOR inhibitor, and a CDK4 inhibitor in Phase 1b/2 studies. In addition, the company is developing OP-3136, an orally available KAT6 inhibitor in Phase 1 trials for breast cancer and other solid tumors. Founded in 2006 and headquartered in San Francisco, California, the company changed its name from CombiThera, Inc. in 2009.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-OLMA
|
$10.97
|
-5.2% Downside
|
Fair
|
$40.70
|
251.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 11, 2026
|
-5.5x
|
2.1x
|
—
|
991.4 M
|
511.8 M
|
0.4%
|
73.5%
|
10.0
|
—
|
80.3%
|
